Back to GetFilings.com
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
(Mark one)
[x] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2002
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _________________to _____________
Commission File Number 0-16132
CELGENE CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 22-2711928
- ------------------------------- ----------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification
Number)
7 Powder Horn Drive, Warren, NJ 07059
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 732-271-1001.
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes _x__ No ___
At October 31, 2002, 78,698,844 shares of Common Stock par value $.01 per share,
were outstanding.
CELGENE CORPORATION
INDEX TO FORM 10-Q
Page No.
PART I FINANCIAL INFORMATION
Item I Unaudited Consolidated Financial Statements
Consolidated Balance Sheets
as of September 30, 2002 (unaudited)
and December 31, 2001 3
Consolidated Statements of Operations
- Three-Month Period Ended
September 30, 2002 and 2001 (unaudited) 4
Consolidated Statements of Operations
- Nine-Month Period Ended
September 30, 2002 and 2001 (unaudited) 5
Consolidated Statements of Cash Flows
- Nine-Month Period Ended
September 30, 2002 and 2001 (unaudited) 6
Notes to Unaudited Consolidated
Financial Statements 8
Item 2 Management's Discussion and Analysis of
Financial Condition and Results of Operations 13
Item 3 Quantitative and Qualitative Disclosures
About Market Risk 22
Item 4 Controls and Procedures 24
PART II OTHER INFORMATION 25
Signatures 26
2
CELGENE CORPORATION
CONSOLIDATED BALANCE SHEETS
September 30, 2002 December 31, 2001
------------------ -----------------
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 100,651,224 $ 47,141,291
Marketable securities available for sale 188,292,686 262,900,049
Accounts receivable, net of allowance of $1,142,296 and $998,395
at September 30, 2002 and December 31, 2001, respectively 13,593,441 13,415,101
Inventory 5,373,654 3,603,462
Other current assets 10,488,038 9,362,423
------------- -------------
Total current assets 318,399,043 336,422,326
Plant and equipment, net 16,378,104 10,645,647
Notes receivable 8,500,000 --
Other assets 8,103,184 6,914,445
------------- -------------
Total assets $ 351,380,331 $ 353,982,418
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 9,049,863 $ 10,831,464
Accrued expenses 15,922,629 13,667,022
Current portion of capital leases and note obligation 90,505 586,731
Current portion of deferred revenue 1,451,971 4,882,668
------------- -------------
Total current liabilities 26,514,968 29,967,885
Long term convertible notes -- 11,713,600
Capitalized leases and note obligation, net of current portion -- 46,215
Other non-current liabilities 2,869,637 1,829,251
------------- -------------
Total liabilities 29,384,605 43,556,951
------------- -------------
Stockholders' equity:
Preferred stock, $.01 par value per share,
5,000,000 authorized; none outstanding at
September 30, 2002 and December 31, 2001, respectively -- --
Common stock, $.01 par value per share
120,000,000 shares authorized;
issued and outstanding 78,614,106 and 75,574,785 shares
at September 30, 2002 and December 31, 2001, respectively 786,141 755,748
Common stock in treasury, at cost; none at September 30, 2002,
and 282 shares at December 31, 2001 -- (2,804)
Additional paid-in capital 543,058,623 527,023,001
Accumulated deficit (225,941,331) (222,367,088)
Deferred compensation (197,689) (1,592,490)
Notes receivable from stockholders (42,000) (42,000)
Accumulated other comprehensive income 4,331,982 6,651,100
------------- -------------
Total stockholders' equity 321,995,726 310,425,467
------------- -------------
Total liabilities and stockholders' equity $ 351,380,331 $ 353,982,418
============= =============
See accompanying notes to unaudited consolidated financial statements.
3
CELGENE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Month Period Ended September 30,
--------------------------------------
2002 2001
------------ ------------
Revenue:
Product sales $ 30,895,532 $ 21,694,656
Collaborative agreements 3,362,414 3,857,972
Related-party collaborative agreements -- 625,005
------------ ------------
Total revenue 34,257,946 26,177,633
------------ ------------
Expenses:
Cost of goods sold 4,428,845 3,231,456
Research and development 20,549,135 18,377,619
Selling, general and administrative 15,738,009 16,730,965
------------ ------------
Total expenses 40,715,989 38,340,040
------------ ------------
Operating loss (6,458,043) (12,162,407)
Other income and expense:
Interest and other income 5,432,645 5,843,986
Interest expense 11,103 23,205
------------ ------------
Net loss $ (1,036,501) $ (6,341,626)
============ ============
Net loss per share of common stock:
Basic and diluted $ (0.01) $ (0.08)
============ ============
Weighted average number of shares of
common stock outstanding 78,583,000 75,356,000
============ ============
See accompanying notes to unaudited consolidated financial statements.
4
CELGENE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Nine Month Period Ended September 30,
-------------------------------------
2002 2001
------------- -------------
Revenue:
Product sales $ 88,892,723 $ 57,383,731
Collaborative agreements 9,679,998 13,225,394
Related-party collaborative agreements -- 1,898,605
------------- -------------
Total revenue 98,572,721 72,507,730
Expenses:
Cost of goods sold 12,203,060 8,766,149
Research and development 57,584,532 47,306,438
Selling, general and administrative 50,153,727 41,122,061
------------- -------------
Total expenses 119,941,319 97,194,648
------------- -------------
Operating loss (21,368,598) (24,686,918)
Other income and expense:
Interest and other income 17,820,626 16,112,142
Interest expense 26,271 73,381
------------- -------------
Net loss $ (3,574,243) $ (8,648,157)
============= =============
Net loss per share of common stock:
Basic and diluted $ (0.05) $ (0.12)
============= =============
Weighted average number of shares of
common stock outstanding 76,872,000 74,973,000
============= =============
See accompanying notes to unaudited consolidated financial statements.
5
CELGENE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine Month Period Ended Sept. 30,
2002 2001
------------- -------------
Cash flows from operating activities:
Net loss $ (3,574,243) $ (8,648,157)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation and amortization of long-term assets 4,807,703 3,563,999
(Recovery)provision for accounts receivable allowances (1,264) 530,669
Realized gain on marketable securities available
for sale (4,283,964) (1,019,175)
Non-cash stock-based compensation 1,375,275 2,682,766
Amortization of premium/discount on marketable securities
available for sale, net 303,260 185,143
Shares issued for employee benefit plans 965,760 741,509
Change in current assets & liabilities:
Increase in accounts receivable (177,075) (1,743,359)
(Increase)decrease in inventory (1,770,192) 65,085
(Increase)decrease in other operating assets (3,408,836) 5,064,084
Increase(decrease) in accounts payable and
accrued expenses 1,514,390 (988,446)
Decrease in deferred revenue (3,430,697) (10,491,362)
------------- -------------
Net cash used in operating activities (7,679,883) (10,057,244)
------------- -------------
Cash flows from investing activities:
Capital expenditures (9,445,678) (6,289,181)
Increase in notes receivable (8,500,000) --
Proceeds from sales and maturities of marketable
securities available for sale 116,384,580 119,789,801
Purchases of marketable securities
available for sale (40,115,630) (228,473,743)
------------- -------------
Net cash provided by(used in) investing activities 58,323,272 (114,973,123)
------------- -------------
Cash flows from financing activities:
Proceeds from exercise of common stock
options and warrants 3,410,532 5,833,852
Repurchase of employee stock options (1,547) --
Repayment of capital lease and note obligation (542,441) (699,519)
------------- -------------
Net cash provided by financing activities 2,866,544 5,134,333
------------- -------------
Net increase (decrease) in cash and cash
equivalents 53,509,933 (119,896,034)
Cash and cash equivalents at beginning of period 47,141,291 161,393,835
------------- -------------
Cash and cash equivalents at end of period $ 100,651,224 $ 41,497,801
============= =============
See accompanying notes to unaudited consolidated financial statements.
6
CELGENE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
(Unaudited)
Nine Month Period Ended September 30,
2002 2001
------------- -------------
Supplemental schedule of non-cash investing and
financing activity:
Change in net unrealized gain on marketable
securities available for sale $ (2,319,118) $ 6,423,164
============= =============
Conversion of convertible notes $ 11,713,600 $ --
============= =============
Deferred compensation related to stock options $ 293,895 $ 457,846
============= =============
Supplemental disclosure of cash flow information:
Interest paid $ 26,271 $ 73,381
============= =============
See accompanying notes to unaudited consolidated financial statements.
7
CELGENE CORPORATION
Notes to Unaudited Consolidated Financial Statements
September 30, 2002
1. Basis of Presentation
---------------------
The unaudited consolidated financial statements have been prepared
from the books and records of Celgene Corporation and subsidiaries ("Celgene" or
the "Company") in accordance with accounting principles generally accepted in
the United States of America for interim financial information pursuant to Rule
10-01 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required for complete annual financial statements.
In the opinion of management, all adjustments (consisting only of
normal recurring accruals) considered necessary for a fair presentation have
been included. Interim results may not be indicative of the results that may be
expected for the year. Certain adjustments and reclassifications were made to
conform to the current year presentation.
The interim consolidated financial statements should be read in
conjunction with the consolidated financial statements and notes thereto
included in the Company's latest annual report on Form 10K.
2. Earnings per Share
------------------
"Basic" earnings (loss) per common share equals net income (loss)
divided by weighted average common shares outstanding during the period. The
Company's basic and diluted per share amounts for the three and nine month
periods ended September 30, 2002 and 2001 are the same since the assumed
exercise of stock options and warrants, and the conversion of convertible notes,
the last of which were converted in June 2002, are all anti-dilutive because of
the loss incurred by the Company during these periods. The amount of common
stock equivalents excluded from the calculation were 9,768,103 at September 30,
2002 and 10,378,710 at September 30, 2001.
3. New Accounting Pronouncement
----------------------------
In July 2002, the Financial Accounting Standards Board ("FASB") issued
FAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities.
This Standard supercedes the accounting guidance provided by Emerging Issues
Task Force Issue No. 94-3, Liability Recognition for Certain Employee
Termination Benefits and Other Costs to Exit an Activity (including Certain
Costs Incurred in a Restructuring). FAS No. 146 requires companies to recognize
costs associated with exit activities when they are incurred rather than at the
date of a commitment to an exit or disposal plan. FAS No. 146 is effective for
exit or disposal activities initiated after December 31, 2002; early application
is encouraged. The Company is currently evaluating this Standard.
8
4. Research Collaboration and Investment
-------------------------------------
The Company has two collaborative research agreements with
Anthrogenesis Corp., a privately held biotechnology company focused on stem cell
commercialization and research, designed to evaluate the application of
Celgene's product pipeline in the stem cell therapy field. During the second
quarter, Celgene and Anthrogenesis Corp. entered into a purchase option
agreement. In addition, Celgene signed an agreement with Anthrogenesis to invest
$6 million in the form of notes which would be convertible into common stock if
the purchase option agreement was not executed. The notes would be convertible
at the option of Anthrogenesis except that at no time can the conversion result
in an ownership by Celgene of more than 19.9%. The initial conversion rate is
$8.035 and is subject to adjustment. The notes have a term of three years and
bear interest at the prime rate plus 2%. The agreement was amended in September
2002 to provide for a total investment in convertible notes of $11.0 million.
The investment secures an option for Celgene to purchase all the outstanding
shares of Anthrogenesis Corp. In September 2002, the respective Boards of
Directors of Celgene and Anthrogenesis approved a plan of merger. Celgene will
issue common shares at a minimum exchange ratio of .4545 of a share of Celgene
common stock for each share of Anthrogenesis common stock, and stock options and
warrants at the same exchange ratio for each outstanding Anthrogenesis stock
option and warrant. Based on this exchange ratio and the Anthrogenesis common
stock, options and warrants outstanding at November 11, 2002, Celgene will issue
approximately 1.5 million shares of common stock and approximately 1.2 million
stock options and warrants. Should Anthrogenesis achieve certain performance
objectives prior to closing, the exchange ratio could be adjusted by
approximately 10%. Completion of the merger, which is subject to certain
conditions, is anticipated by year end. As of September 30, 2002, $8.5 million
in convertible notes and $0.5 million in research funding has been provided to
Anthrogenesis. Anthrogenesis is considered a related party as a senior executive
of the Company serves on the Board of Directors of Anthrogenesis.
5. Marketable Securities Available for Sale
----------------------------------------
The amortized cost, gross unrealized holding gains, gross unrealized
holding losses and fair value of available for sale securities by major security
type at September 30, 2002 and December 31, 2001 were as follows:
Gross Gross Estimated
September 30, 2002 Amortized Unrealized Unrealized Fair
Cost Gain Loss Value
------------ ------------ ------------ ------------
Government agencies $ 149,906 $ 994 $ -- $ 150,900
Government bonds and notes 553,594 9,609 -- 563,203
Corporate debt securities 183,257,204 9,390,768 (5,069,389) 187,578,583
------------ ------------ ------------ ------------
Total $183,960,704 $ 9,401,371 $ (5,069,389) $188,292,686
============ ============ ============ ============
9
Gross Gross Estimated
December 31, 2001 Amortized Unrealized Unrealized Fair
Cost Gain Loss Value
------------ ------------ ------------ ------------
Government agencies $ 24,668,882 $ 318,218 $ -- $ 24,987,100
Government bonds and notes 553,594 15,076 -- 568,670
Corporate debt
securities 231,026,473 7,603,951 (1,286,145) 237,344,279
------------ ------------ ------------ ------------
Total $256,248,949 $ 7,937,245 $ (1,286,145) $262,900,049
============ ============ ============ ============
6. Inventory
---------
September 30, December 31,
2002 2001
------------- ------------
Raw materials $2,234,707 $ 763,662
Work in process 759,344 1,710,305
Finished goods 2,379,603 1,129,495
---------- ----------
Total $5,373,654 $3,603,462
========== ==========
7. Convertible Notes
-----------------
On January 20, 1999, the Company issued to an institutional investor
convertible notes in the amount of $15,000,000. The notes had a five year term
and a coupon rate of 9% with interest payable on a semi-annual basis. The notes
contained a conversion feature that allowed the note holders to convert the
notes into common shares after one year at $6 per share. During 2000,
$13,286,400 of the notes were converted into 2,214,399 common shares. During
June 2002, the remaining notes, having a carrying value of $1,713,600, were
converted into 285,601 common shares.
On July 6, 1999, the Company issued to the same institutional investor
convertible notes in the amount of $15,000,000. The notes had a five year term
and a coupon rate of 9% with interest payable on a semi-annual basis. The notes
contained a conversion feature that allowed the note holders to convert the
notes into common shares after one year at $6.33 per share. During 2000,
$5,000,000 of the notes were converted to 789,474 common shares. During June
2002, the remaining notes, having a carrying value of $10,000,000, were
converted into 1,578,948 common shares.
10
8. Comprehensive Income(Loss)
--------------------------
Comprehensive income (loss) includes net loss and other comprehensive
income (loss) which refers to those revenues, expenses, gains and losses which
are excluded from net loss. Other comprehensive income (loss) includes net
unrealized gains and losses on marketable securities classified as
available-for-sale.
Three Month Period Ended
----------------------------------------
September 30, 2002 September 30, 2001
------------------ ------------------
Net loss $(1,036,501) $(6,341,626)
Other comprehensive income (loss):
Unrealized holding gains
arising during the period 6,286,941 6,421,078
Less: reclassification adjustment
for gains included in net
loss (1,505,504) (544,500)
----------- -----------
Net unrealized gain on
securities 4,781,437 5,876,578
----------- -----------
Total comprehensive income (loss) $ 3,744,936 $ (465,048)
=========== ===========
Nine Month Period Ended
----------------------------------------
September 30, 2002 September 30, 2001
------------------ ------------------
Net loss $(3,574,243) $(8,648,157)
Other comprehensive income (loss):
Unrealized holding gains
arising during the period 1,964,846 7,442,339
Less: reclassification adjustment
for gains included in net
loss (4,283,964) (1,019,175)
----------- -----------
Net unrealized gain (loss) on
securities (2,319,118) 6,423,164
----------- -----------
Total comprehensive loss $(5,893,361) $(2,224,993)
=========== ===========
11
9. Stockholders' Equity
--------------------
Warrants to Acquire Common Stock
Under the terms of a private placement of Series B Preferred Stock
entered into on June 9, 1997, the Company was obligated to issue warrants to
acquire a number of shares of common stock. As of December 31, 2001, 967,693
warrants remained outstanding and were exercisable at $2.49 per share. During
the second quarter of 2002, all the outstanding warrants were exercised and
converted into common shares.
Deferred Compensation Expense
Prior to the Company's merger with Signal Pharmaceuticals, Inc.,
Signal recorded an aggregate of approximately $9.4 million of deferred
compensation for stock options granted from 1997 through 2000, representing the
difference between the option exercise price and the estimated fair value of the
underlying stock for financial statement presentation purposes. The deferred
compensation is being amortized over the vesting period of the options. Through
September 30, 2002, the Company has recorded approximately $8.0 million of
compensation expense of which approximately $311,000 and $600,000 was recorded
during the three month periods ended September 30, 2002 and 2001, respectively
and approximately $1.1 million and $1.9 million was recorded during the nine
month period ended September 30, 2002 and 2001, respectively. Upon the
termination of certain employees and consultants, the Company reversed
approximately $1.1 million of unamortized deferred compensation relating to
their unvested options through September 2002.
The Company recorded compensation expense relating to stock options
and warrants issued to consultants, advisors or financial institutions and other
stock-based compensation of approximately $138,000 and $165,000 for the three
month periods ended September 30, 2002 and 2001, respectively and approximately
$274,000 and $762,000 for the nine month periods ended September 30, 2002 and
2001, respectively.
10. Subsequent Event
----------------
In October 2002, the Company entered into a co-promotion agreement
with Cell Pathways, Inc. to market and sell Cell Pathway's product, Gelclair(TM)
through Celgene's salesforce. Gelclair is used in the treatment of mucositis, a
common side effect of radiation and chemotherapy regimens used in treating
various cancers. Celgene will receive a percent of the net sales of the product
as defined in the agreement.
12
PART 1 -- FINANCIAL INFORMATION
ITEM 2 -- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
Results of Operations
- ---------------------
Three month period ended September 30, 2002 vs.
Three month period ended September 30, 2001
- -------------------------------------------
Total revenue: Our total revenue for the three months ended September 30, 2002
increased approximately 31% to $34.3 million compared to $26.2 million in the
same period of 2001. Revenue in 2002 consisted of THALOMID(R) sales of $30.5
million, Focalin(TM) sales of $0.4 million, Ritalin(R) product royalties of $1.8
million, and other collaborative agreements revenue of $1.6 million compared to
THALOMID(R) sales of $21.7 million, collaborative agreements revenue of $3.9
million and related-party revenue of $0.6 million in the same period of 2001.
Increasing use of THALOMID(R) by oncologists in the treatment of various types
of cancer contributed to the 42% growth in product sales. The decrease in
collaborative agreements revenue is primarily attributable to the completion of
the amortization in November 2001 of the up-front payment from Novartis Pharma
AG related to the license agreement on Focalin(TM). Related-party revenue
declined in 2002 as a result of the initial term of our agreement with Axys Inc.
ending in October 2001. The agreement has not been extended.
Cost of goods sold: Cost of goods sold during the three months ended
September 30, 2002 was $4.4 million or 14.5% as a percent of product sales
compared with approximately $3.2 million or 14.9% as a percent of product sales
in the comparable period in 2001. The decrease in cost of goods sold as a
percent of product sales is attributable to more favorable quality control and
quality assurance costs and lower freight costs related to THALOMID sales. Cost
of goods sold for the third quarter of 2002 relating to Focalin(TM) sales was
lower than the normal cost at standard as some manufacturing costs incurred
prior to Focalin's(TM) approval in November 2001 were expensed as research and
development expenses. This favorable treatment will continue until the cost
associated with the quantity previously expensed is completely sold.
Research and development expenses: Research and development expenses
consist primarily of salaries and benefits, contractor fees, principally with
contract research organizations to assist in our clinical development programs,
clinical drug supplies for our clinical and preclinical programs as well as
other consumable research supplies, and allocated facilities charges such as
building rent and utilities. Research and development expenses for the third
13
quarter of 2002 increased 12% to $20.5 million from $18.4 million in 2001.
During the third quarter of 2002, approximately $12.2 million was spent on
THALOMID(R) and the IMiDs(R) and SelCIDs(TM), primarily for preclinical
toxicology, phase I/II and phase III clinical trials and regulatory expenses. We
spent approximately $8.3 million in our gene regulation, target discovery and
agro-chemical programs, primarily for internal headcount related expenses,
laboratory supplies and product development costs.
As a percent of total revenue, research and development expenses were
approximately 60% and 70% for the three month periods ended September 30, 2002
and 2001, respectively. As a result of increasing revenue, research and
development expenses may continue to decrease as a percent of total revenue
although the actual dollar amount will continue to increase as we move our
earlier stage compounds through preclinical and clinical programs. In general,
time to completion of each phase would be as follows:
Phase I ----- 1-2 years
Phase II ---- 2-3 years
Phase III --- 2-3 years
Due to the significant risks and uncertainties inherent in preclinical
tests and clinical trials associated with each of our research and development
projects, the cost to complete such projects is not reasonably estimable. The
data obtained from these tests and trials may be susceptible to varying
interpretation that could delay, limit or prevent a project's advancement
through the various stages of clinical development, which would significantly
impact the costs incurred to bring a project to completion.
Selling, general and administrative expenses: Selling expenses consist
of salaries and benefits for sales and marketing and customer service personnel,
warehousing and distribution costs, and other commercial expenses to support the
sales force and the education and registration efforts underlying the
S.T.E.P.S.(R) (System for Thalidomide Education and Prescribing Safety) program.
The S.T.E.P.S.(R) program requires that all physicians prescribing THALOMID(R),
all pharmacies dispensing THALOMID(R) and all patients being treated with
THALOMID(R) must be included in a registry. Inclusion in the registry in turn
ensures that the physicians, pharmacists and patients have participated in the
education program for the safe and appropriate use of THALOMID(R).
14
General and administrative expenses consist primarily of salaries and
benefits, outside services for legal, audit, tax and investor activities and
allocations of facilities costs, principally for rent, utilities and property
taxes. Selling, general and administrative expenses decreased by approximately
6% for the three months ended September 30, 2002 to $15.7 million from $16.7
million in the same period in 2001. The decrease was due primarily to expenses
associated with the education, registration and validation required for the
rollout of the enhanced S.T.E.P.S.(R) system in September of 2001.
Interest and other income and expense: Interest and other income for
the third quarter of 2002 decreased approximately 7% to approximately $5.4
million from $5.8 million in the same period in 2001. The decrease was primarily
due to lower interest income due to lower interest rates and lower balances of
marketable securities offset by an increase in realized gains on the sale of
securities in the third quarter of 2002.
Interest expense for the third quarter of 2002 decreased to
approximately $11,000 from approximately $23,000 in the same period in 2001. The
decrease was due primarily to the expiration of a three year capital equipment
lease in July 2001.
Net income (loss): We recorded a net loss of $1.0 million in the three
month period ended September 30, 2002 compared to a loss of $6.3 million in the
same period in 2001. The decreased loss was due to increased revenue of $8.1
million offset by the increase in costs and expenses of $2.4 million and the
decrease in interest and other income of $0.4 million.
Nine month period ended September 30, 2002 vs.
Nine month period ended September 30, 2001
- ------------------------------------------
Total revenue: Our total revenue for the nine months ended September
30, 2002 increased 36% to $98.6 million compared with $72.5 million in the same
period of 2001. Revenue in 2002 consisted of THALOMID(R) sales of $85.1 million,
Focalin(TM) sales of $3.8 million, Ritalin(R) product royalties of $3.2 million
and other collaborative agreements revenue of $6.4 million compared with
THALOMID(R) sales of $57.4 million, collaborative agreements revenue of $13.2
million and related-party revenue of $1.9 million in the same period of 2001.
15
Increasing use of THALOMID(R) by oncologists in the treatment of various types
of cancer, especially in multiple myeloma, as well as the $3.8 million of
Focalin(TM) sales in 2002, contributed to the 55% growth in product sales. The
decrease in collaborative agreements revenue is primarily attributable to the
completion of the amortization in November 2001 of the up-front payment on a
research agreement with Novartis Pharma AG. Related-party revenue declined in
2002 as a result of the initial term of our agreement with Axys Inc. ending in
October 2001. The agreement has not been extended.
Cost of goods sold: Cost of goods sold during the first nine months of
2002 was $12.2 million or 13.7% as a percent of product sales compared with
approximately $8.8 million or 15.3% as a percent of product sales in the
comparable period in 2001. The decrease in cost of goods sold as a percent of
product sales is attributable to more favorable quality control and quality
assurance costs and lower freight costs related to THALOMID(R) sales. Cost of
goods sold for the first nine months of 2002 relating to Focalin(TM) sales was
lower than the normal cost at standard as some manufacturing costs incurred
prior to Focalin's(TM) approval in November 2001 were expensed as research and
development expenses. This favorable treatment will continue until the cost
associated with the quantity previously expensed is completely sold.
Research and development expenses: Research and development expenses
increased by 22% for the nine months ended September 30, 2002 to $57.6 million
from $47.3 million in the same period in 2001. During the first nine months of
2002, approximately $32.9 million was spent on THALOMID(R) and the IMiDs(R) and
SelCIDs(TM), primarily for preclinical toxicology, phase I/II and phase III
clinical trials and regulatory expenses. We spent approximately $24.7 million in
our gene regulation, target discovery and agro-chemical programs, primarily for
internal headcount related expenses, laboratory supplies and product development
costs.
As a percent of total revenue, research and development expenses were
approximately 58% and 65% for the nine months ended September 30, 2002 and 2001,
respectively. As a result of increasing revenue, research and development
expenses may continue to decrease as a percent of total revenue although the
actual dollar amount will continue to increase as we move our earlier stage
compounds through preclinical and clinical programs.
16
Selling, general and administrative expenses: Selling, general and
administrative expenses increased by 22% for the nine months ended September 30,
2002 to $50.2 million from $41.1 million in the same period in 2001. The
increase was due primarily to the expansion of the sales and marketing
organization and related expenses, an increase in customer service staff as well
as expenses related to a new customer service and enhanced S.T.E.P.S.(R) system
(System for Thalidomide Education and Prescribing Safety). As a percent of total
revenue, selling, general and administrative expenses were approximately 51% and
57% for the nine month periods ended September 30, 2002 and 2001, respectively.
Interest and other income and expense: interest and other income for
the first nine months of 2002 increased 10.6% to approximately $17.8 million
from $16.1 in the same period in 2001. The increase was primarily due to an
increase in realized gains of $3.3 million on the sale of corporate bonds offset
by lower interest income due to lower interest rates in 2002.
Interest expense for the first nine months of 2002 decreased to
approximately $26,300 from approximately $73,400 in the same period in 2001. The
decrease was due primarily to the expiration of a three year capital equipment
lease in July 2001.
Net loss: The net loss for the nine month period ended September 30,
2002 decreased to $3.6 million from $8.6 million in the same period of 2001. The
decreased loss was due to increased revenue of $26.1 million and higher interest
and other income of approximately $1.7 million offset by the increase in costs
and expenses of approximately $22.7 million.
Liquidity and capital resources: Since inception, we have financed our
working capital requirements primarily through product sales, private and public
sales of our debt and equity securities, income earned on the investment of
proceeds from the sale of such securities and revenue from research contracts
and license and milestone payments. Since our initial product launch in the
third quarter of 1998, we have recorded net product sales totaling approximately
$263.0 million through September 30, 2002. We also received $38.5 million from
two separate research and license agreements from 2000 through 2002.
Our net working capital at September 30, 2002 decreased approximately
5% to $291.9 million from $306.5 million at December 31, 2001. The decrease in
17
working capital was primarily due to lower total cash, cash equivalents and
marketable securities and deferred revenue offset by higher inventories and
other current assets, principally prepaid insurance and other prepaids.
Cash and cash equivalents increased to $100.7 million in the first nine
months of 2002 from $47.1 million at December 31, 2001 while investments in
marketable debt securities decreased to $188.3 million from $262.9 million in
the same period. Total cash, cash equivalents and marketable securities
decreased by approximately $21.1 million reflecting the increase in research and
development and selling, general and administrative spending during the first
nine months of 2002 as well as a decrease in the unrealized gain on our
marketable securities portfolio of $2.3 million reflecting current market
conditions.
We expect that our rate of spending will increase as the result of
research and product development spending, increased clinical trial costs,
increased expenses associated with the regulatory approval process and
commercialization of products currently in development, increased costs related
to the commercialization of THALOMID(R) and increased capital investments. Our
current funds, combined with the increasing revenue from sales of THALOMID(R),
revenue from the Ritalin(R) products associated with the Novartis collaboration
and various research agreements and collaborations are expected to provide
sufficient capital for our operations for the foreseeable future.
Contractual Obligations
Our major outstanding contractual obligations relate to our operating
(facilities) leases. Our facilities lease expense in future years will increase
over previous years as a result of a new lease arrangement entered into in
December 2001.
We lease a 44,500-square foot laboratory and office facility in Warren,
New Jersey, under a lease with an unaffiliated party, which has a term ending in
May 2007 with two five-year renewal options, and an adjoining 29,000-square foot
facility which has a term ending in July 2010 with two five-year renewal
options. Monthly rental expenses at this site are approximately $64,000. We also
lease an 18,000-square foot laboratory and office facility in North Brunswick,
New Jersey, under a lease with an unaffiliated party that has a term ending in
December 2009 with two five-year renewal options. Monthly rental expenses for
this facility are approximately $46,000. We believe that our laboratory
18
facilities are adequate for our research and development activities for at least
the next 12 months. During the third quarter 2002, we entered into a lease for
an additional 11,400 square feet in a nearby facility. Monthly rental expense is
approximately $17,000.
We also lease offices and research facilities in San Diego, California
under three operating lease agreements for our West Coast research operations.
The minimum annual rents are subject to specified annual rental increases. We
also reimburse the lessor for taxes, insurance and operating costs associated
with the leases. Monthly rental expense for these facilities is approximately
$81,000. Under the terms of the lease, we have an outstanding letter of credit
for $150,000 in favor of the lessor, which is fully collateralized by cash. In
December 2001, we entered into a new ten-year lease for a 78,200 square foot
facility to consolidate our West Coast research operations into one building. We
commenced occupation of that facility in the fourth quarter 2002. Monthly rental
expense of approximately $172,000 for the new facility began in mid September
2002. We intend to sublease the current facilities until the leases expire in
December 2003.
We have entered into agreements with various contractors to improve the
new facility we are leasing in San Diego, California. Under such agreements, we
have contracted to spend approximately $6.7 million for tenant improvements in
the new research facility. We expect to expend funds in the approximate amount
of $1.5 million for the remainder of this project over the next three months.
This project is being funded through our current capital resources.
Critical Accounting Policies
In December 2001, the SEC requested that all registrants discuss their
most "critical accounting policies" in Management's Discussion and Analysis of
Financial Condition and Results of Operations. The SEC indicated that a
"critical accounting policy" is one which is both important to the portrayal of
the company's financial condition and results and requires management's most
difficult, subjective or complex judgments, often as a result of the need to
make estimates about the effect of matters that are inherently uncertain. While
our significant accounting policies are more fully described in Note 2 to our
19
consolidated financial statements included in our annual report on form 10K, we
believe the following accounting policy to be critical:
Revenue Recognition. We have formed collaborative research and
development agreements and alliances with several pharmaceutical companies.
These agreements are in the form of research and development and license
agreements. The agreements are for both early and late stage compounds and are
focused on specific disease areas. For the early stage compounds, the agreements
are relatively short term agreements that are renewable depending on the success
of the compounds as they move through preclinical development. The agreements
call for nonrefundable upfront payments, milestone payments on achieving
significant milestone events, and in some cases on going research funding. The
agreements also contemplate royalty payments on sales if and when the compound
receives FDA marketing approval.
In accordance with Staff Accounting Bulletin No. 101 ("SAB 101")
Revenue Recognition in Financial Statements, upfront payments are recorded as
deferred revenue and recognized over the estimated service period. If the
estimated service period is subsequently modified, the period over which the
upfront fee is recognized is modified accordingly on a prospective basis.
Revenue from the achievement of research and development milestones, which
represent the achievement of a significant step in the research and development
process, are recognized when and if the specific milestones are achieved.
Continuation of certain contracts is dependent upon our achieving specific
contractual milestones; however, none of the payments received to date are
refundable regardless of the outcome of the project. Research funding is
recorded in the period during which the expenses covered by the funding
occurred.
Certification of Financial Statements
The certifications by the Company's Chief Executive Officer and Chief
Financial Officer of this report on Form 10-Q as required by section 906 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), have been submitted to the
Securities and Exchange Commission as additional correspondence accompanying
this report.
Cautionary Statements for Forward-Looking Information
The Management's Discussion and Analysis of Financial Condition and
Results of Operations provided above contains certain forward-looking statements
20
which involve known and unknown risks, delays, uncertainties and other factors
not under our control which may cause actual results, performance and
achievements of Celgene to be materially different from the results, performance
or other expectations implied by these forward-looking statements. These factors
include the results of current or pending clinical trials, actions by the FDA
and other factors detailed herein and in our other filings with the Securities
and Exchange Commission.
21
Item 3 - Quantitative and Qualitative Disclosures About Market Risk
Our holdings of financial instruments are comprised of commercial paper and U.S.
government and corporate securities. These financial instruments may be
classified as securities available for sale and carried at fair value or held to
maturity and carried at amortized cost depending upon our intent. Securities
classified as available for sale are held for an indefinite period of time and
are intended to be used to meet the ongoing liquidity needs of the Company.
Unrealized gains and losses (which are deemed to be temporary) on available for
sale securities, if any, are reported as a separate component of stockholders'
equity. The cost of all debt securities is adjusted for amortization of premiums
and accretion of discounts to maturity. The amortization, along with realized
gains and losses, is included in interest income and other income. We do not use
financial derivatives for investment or trading purposes. As of September 30,
2002, all securities have been classified as available for sale.
We have established guidelines relative to diversification and maturities to
maintain safety and liquidity. These guidelines are reviewed periodically and
may be modified depending on market conditions. Although our investments are
subject to credit risk, our Investment Policy specifies credit quality standards
for our investments and limits the amount of credit exposure from any single
issue, issuer or type of investment. Our investments are also subject to
interest rate risk and will decrease in value if market interest rates increase.
Due to the limited number of foreign currency transactions, our foreign exchange
currency risk is minimal.
22
The table below presents the principal amounts and related weighted average
interest rates by year of maturity for our investment portfolio as of September
30, 2002:
2007 and
2003 2004 2005 2006 beyond Total Fair Value
-------- -------- -------- -------- -------- -------- ----------
(in Thousands $)
Fixed Rate $ 20,800 $ -- $ 20,510 $ 64,345 $ 76,775 $182,430 $186,293
Average Interest
Rate 6.76% -- 8.02% 6.78% 7.25% 7.11%
Variable Rate -- -- -- -- $ 2,000 $ 2,000 $ 2,000
Average Interest
Rate -- -- -- -- 8.00% 8.00%
-------- -------- -------- -------- -------- -------- --------
Total $ 20,800 $ -- $ 20,510 $ 64,345 $ 78,775 $184,430 $188,293
The fair value of fixed interest rate instruments are affected by changes in
interest rates.
23
Item 4. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures. Celgene
Corporation's principal executive officer and principal financial
officer have concluded that the Company's disclosure controls and
procedures (as defined in Rule 13a-14(c) and 15d-14(c) under the
Securities Exchange Act of 1934, as amended), based on their
evaluation of these controls and procedures as of a date within
ninety (90) days prior to the filing date of this Form 10-Q, are
effective.
(b) Changes in Internal Controls. There have been no significant
changes in Celgene Corporation's internal controls or in other
factors that could significantly affect these controls subsequent
to the date of the evaluation thereof, including any corrective
actions with regard to significant deficiencies and material
weaknesses.
24
PART II -- OTHER INFORMATION
Item 1. -- None
Item 2. -- None
Item 3. -- None
Item 4. -- None
Item 5. -- Other Information:
None
Item 6. Exhibits
10.1 Amendment No. 1 to 1992 Long-Term Incentive Plan, effective as of June
22, 1999.
10.2 Amendment No. 1 to 1995 Non-Employee Directors' Incentive Plan,
effective as of June 22, 1999.
10.3 Amendment No. 2 to 1995 Non-Employee Directors' Incentive Plan,
effective as of April 18, 2000.
25
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CELGENE CORPORATION
DATE November 13, 2002 BY /s/ Robert J. Hugin
----------------- --------------------------
Robert J. Hugin
Senior Vice President
Chief Financial Officer
DATE November 13, 2002 BY /s/ James R. Swenson
----------------- --------------------------
James R. Swenson
Controller
(Chief Accounting Officer)
26
Certifications
I, John W. Jackson, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Celgene
Corporation;
2. Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for the periods presented in
this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
we have:
a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this
quarterly report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the
filing date of this quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on
our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based
on our most recent evaluation, to the registrant's auditors and the
audit committee of registrant's Board of Directors (or persons
performing the equivalent function):
a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's
ability to record, process, summarize and report financial data
and have identified for the registrant's auditors any material
weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal controls;
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in
internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant
deficiencies and material weaknesses.
Date: November 13, 2002
/s/ John W. Jackson
-----------------------
John W. Jackson
Chairman of the Board
Chief Executive Officer
I, Robert J. Hugin, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Celgene
Corporation;
2. Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for the periods presented in
this quarterly report;
4. The registrant's other certifying officers and I are
responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and we have:
a. designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this
quarterly report is being prepared;
b. evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the
filing date of this quarterly report (the "Evaluation Date"); and
c. presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on
our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based
on our most recent evaluation, to the registrant's auditors and the
audit committee of registrant's Board of Directors (or persons
performing the equivalent function):
a. all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's
ability to record, process, summarize and report financial data
and have identified for the registrant's auditors any material
weaknesses in internal controls; and
b. any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal controls;
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in
internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant
deficiencies and material weaknesses.
Date: November 13, 2002
/s/ Robert J. Hugin
-----------------------
Robert J. Hugin
Chief Financial Officer
EXHIBIT
NO. EXHIBIT DESCRIPTION
- ------- -------------------
10.1 Amendment No. 1 to 1992 Long-Term Incentive Plan, effective as of June
22, 1999.
10.2 Amendment No. 1 to 1995 Non-Employee Directors' Incentive Plan,
effective as of June 22, 1999.
10.3 Amendment No. 2 to 1995 Non-Employee Directors' Incentive Plan,
effective as of April 18, 2000.